🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Florida
Clinical trial register · United States · industry-sponsored

Clinical Trials in Florida, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca173 Eli Lilly and Company150 Merck Sharp & Dohme LLC116 AbbVie112 Novartis Pharmaceuticals107
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in Florida

4401 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Lighthouse Pharmaceuticals, Inc.
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Kansas, Louisiana, Maryland
2025-02-17
Recruiting
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
NCT06778447Degenerative Disc Disease, Disc Degeneration, Lumbar Discogenic Pain
VIVEX Biologics, Inc.
Not applicable
325
California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky, Louisiana
2025-02-17
Active, closed
ATA-200 Gene Therapy Trial in Patients With LGMDR5
NCT05973630LGMD2C
Atamyo Therapeutics
Phase 1
4
Florida
2025-02-15
Recruiting
MB-105 in Patients With CD5 Positive T-cell Lymphoma
NCT06534060Lymphoma, T-Cell
March Biosciences Inc
Phase 2
46
California, Colorado, Florida, Iowa, Massachusetts, Nebraska, New York, North Carolina
2025-02-15
Active, closed
Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC
NCT06811909Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis
BioStem Technologies
Not applicable
71
Alabama, California, Florida, Illinois, Massachusetts, Missouri, New York, Texas
2025-02-14
Recruiting
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505Chronic Migraine
DrugAtogepant
AbbVie
Phase 3
420
Alabama, Arkansas, California, Florida, Indiana, Michigan, Mississippi, Nebraska
2025-02-13
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819Advanced Solid Tumors, HER2 Mutation
Bayer
Phase 2
111
Alabama, California, Florida, Massachusetts, Michigan, Ohio, Tennessee, Texas
2025-02-13
Recruiting
IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers
NCT06616844Wound Heal, Ulcer
ConvaTec Inc.
Not applicable
235
California, Florida, Indiana, Maryland, Massachusetts, New York, North Carolina, Pennsylvania
2025-02-12
Recruiting
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
NCT06765668Parkinson Disease
Impax Laboratories, LLC
Phase 4
220
Arizona, Arkansas, California, Florida, Illinois, Kansas, Michigan, Nevada
2025-02-12
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
DrugLP352
Longboard Pharmaceuticals
Phase 3
324
Arkansas, California, Colorado, Florida, Idaho, Maryland, Massachusetts, Minnesota
2025-02-12
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
231
California, Florida, Georgia, Idaho, Illinois, Indiana, Missouri, New York
2025-02-12
Recruiting
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
NCT06822738Primary Open Angle Glaucoma
AbbVie
Phase 3
130
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana
2025-02-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
NCT06770933Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Vantage Biosciences Ltd
Phase 2
100
California, Florida, Illinois, Maryland, Pennsylvania, Virginia
2025-02-11
Recruiting
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
NCT06942572Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
Splice Bio
Phase 1/2
57
Colorado, Florida, Massachusetts, Oregon, Texas
2025-02-11
Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy
DrugClaseprubart
Dianthus Therapeutics
Phase 3
256
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Hawaii, Illinois
2025-02-10
Active, closed
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053Asthma
DrugGSK5784283
GlaxoSmithKline
Phase 2
307
Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Michigan
2025-02-10
Recruiting
This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.
NCT06616025Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
Neuraptive Therapeutics Inc.
Phase 3
98
California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri
2025-02-10
Recruiting
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
NCT06849258Benign Prostatic Hyperplasia
Rivermark Medical
Not applicable
215
California, Colorado, Florida, Illinois, Louisiana, Michigan, Nevada, New York
2025-02-10
Recruiting
Evaluation of a Switchable Acrylic Adhesive Drape for Safer Removal in Negative Pressure Wound Therapy Applications.
NCT06717308Frequency and Type of Medical Adhesive-Related Skin Injury, NPWT Drape Seal Effectiveness Rate (or Leak Incidence Rate), Clinician Acceptability of New NPWT Drape, Patient Drop-out Rate From Prescribed NPWT Treatment
Global Biomedical Technologies, LLC
Not applicable
300
California, Florida, New York
2025-02-10
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
NCT06707610Advanced Cancer, Advanced Solid Tumor
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1
234
Florida, Virginia
2025-02-10
Recruiting
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
NCT06812078Idiopathic Hypersomnia
DrugTAK-360
Takeda
Phase 2
96
California, Colorado, Florida, Missouri, North Carolina, Ohio, South Carolina, Texas
2025-02-07
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Genmab
Phase 3
530
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-02-07
Recruiting
The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery
NCT06837298Muscle Damage, Muscle
PepsiCo Global R&D
Not applicable
76
Florida
2025-02-07
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
Pathos AI, Inc.
Phase 1/2
120
California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-02-07
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Arizona, California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan
2025-02-07
Active, closed
Pivotal Clinical Trial Evaluating the Safety and Efficacy of the Fully Implanted Acclaim Cochlear Implant
NCT06699797Sensori-Neural Deafness, Sensorineural Hearing Loss, Sensorineural Hearing Loss (Disorder), Sensorineural Hearing Loss, Bilateral
Envoy Medical Corporation
Not applicable
56
Arizona, California, Florida, Minnesota, Ohio, Oklahoma, South Carolina
2025-02-06
Recruiting
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368Aortic Stenosis
Medtronic Cardiovascular
Observational
225
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana
2025-02-06
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
216
Alabama, California, Florida, Illinois, Kentucky, Louisiana, Maryland, Ohio
2025-02-06
Recruiting
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
NCT06793371Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Cytokinetics
Phase 2
60
Alabama, Arizona, Arkansas, California, Florida, Illinois, Louisiana, Massachusetts
2025-02-06
Recruiting
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Phase 1/2
108
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2025-02-06
Recruiting
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
NCT06800313Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2
190
Colorado, Connecticut, Florida, Louisiana, Massachusetts, Michigan, Nebraska, New York
2025-02-06
Active, closed
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
NCT06843239Systemic Sclerosis (SSc), Scleroderma
Zura Bio Inc
Phase 2
80
California, Florida, Iowa, Massachusetts, Michigan, Texas
2025-02-06
Active, closed
Remote Temperature and Visual Monitoring To Help Manage Diabetic Foot Ulcers
NCT06782386Diabetic Foot Ulcer (DFU)
Bluedrop Medical Limited
Not applicable
100
Florida, Pennsylvania
2025-02-05
Recruiting
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT06830629Proteinuric Kidney Disease
Maze Therapeutics
Phase 2
74
Alabama, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas, Kentucky
2025-02-05
Recruiting
Speech Understanding and Listening Effort Benefits of Hearing Instruments
NCT07116135Hearing Loss, Bilateral
Sonova AG
Not applicable
30
Florida
2025-02-05
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-02-05
Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287Lung Cancer, Breast Cancer
DrugsPumitamig·Iza-bren·Osimertinib·Nivolumab
Bristol-Myers Squibb
Phase 1/2
416
Alabama, Florida, Iowa, Missouri, New Jersey, Ohio, Oregon, Pennsylvania
2025-02-04
Active, closed
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT06709014Early Alzheimers Disease
DrugBuntanetap/posiphen
Annovis Bio Inc.
Phase 3
760
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-02-04
Recruiting
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06720987KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
DrugsKQB198·Pemetrexed
Kumquat Biosciences Inc.
Phase 1
140
Arizona, Colorado, Florida, Massachusetts, Michigan, Minnesota, Ohio, Oklahoma
2025-02-04
Active, closed
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325Thyroid Eye Disease (TED)
DrugVRDN-003
Viridian Therapeutics, Inc.
Phase 3
320
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2025-02-03
Active, closed
WATER IV Prostate Cancer
NCT06651632Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
280
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-02-03
Recruiting
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT06547489Major Depressive Disorder
DrugZelquistinel
Syndeio Biosciences, Inc
Phase 2
164
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2025-02-03
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
DrugsPumitamig·Atezolizumab·Etoposide·Carboplatin
BioNTech SE
Phase 3
621
Arizona, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana
2025-02-03
Recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563Glioblastoma
DrugsTemozolomide·Pembrolizumab
NovoCure GmbH
Phase 3
741
Arizona, California, District of Columbia, Florida, Illinois, Kentucky, Maryland, Massachusetts
2025-02-03
Active, closed
Clinical Study to Assess the Effects of Prebiotic and Probiotic Supplement
NCT06794619Healthy
Olly, PBC
Not applicable
34
Florida
2025-02-03
Recruiting
Non-Invasive Preeclampsia Screening and Biobank
NCT06643741Preeclampsia (PE)
Sequenom, Inc.
Observational
6,550
Arizona, Delaware, Florida, Louisiana, Massachusetts, New Jersey, New York, North Carolina
2025-02-02
Recruiting
Study of Olutasidenib and Temozolomide in HGG
NCT06161974High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
DrugOlutasidenib
Rigel Pharmaceuticals
Phase 2
60
Colorado, District of Columbia, Florida, Illinois, Massachusetts, North Carolina, Ohio, Pennsylvania
2025-02-01
Recruiting
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527Rotator Cuff Tears of the Shoulder
Anika Therapeutics, Inc.
Not applicable
150
Arizona, California, Florida, Georgia, Indiana, Maryland, New Jersey, South Carolina
2025-02-01
Recruiting
Pediatric Down Syndrome Post-Approval Study
NCT06851338Pediatric Obstructive Sleep Apnea, Down Syndrome (DS)
Inspire Medical Systems, Inc.
Not applicable
60
Arizona, California, Florida, New York, Ohio, Texas
2025-02
Active, closed
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06769048Geographic Atrophy
Boehringer Ingelheim
Phase 2
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-01-31
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugsRemibrutinib A·Remibrutinib B
Novartis Pharmaceuticals
Phase 3
588
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-01-31
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
NCT06514794T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Allotera Therapeutics
Phase 2
125
California, Colorado, District of Columbia, Florida, Georgia, Missouri, New York, Ohio
2025-01-31
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
California, District of Columbia, Florida, South Carolina, Tennessee, Texas, Virginia
2025-01-29
Active, closed
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595Generalized Anxiety Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
245
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New Jersey, Ohio
2025-01-29
Recruiting
Tissue Repair Gel in Venous Leg Ulcers (US)
NCT06707090Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis
DrugTR987
TR Therapeutics
Phase 3
312
Arizona, California, Florida, Illinois, Louisiana, Mississippi, New York, North Carolina
2025-01-28
Recruiting
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
NCT06836232Recurrent Pericarditis
Zomagen Biosciences Ltd.
Phase 2
50
California, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio, Texas
2025-01-28
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Alabama, Arizona, California, Colorado, Florida, Iowa, Kansas, Kentucky
2025-01-28
Recruiting
Clinical Outcome Measure at Stryker Spine
NCT06226272Degenerative Disc Disease, Degenerative Scoliosis
VB Spine, LLC
Observational
5,222
Florida, Maine, Michigan, Ohio, Tennessee, Texas
2025-01-28
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Prednisolone·Methylprednisolone
Merck Sharp & Dohme LLC
Phase 3
1,046
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-01-27
Recruiting
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugALKS 2680
Alkermes, Inc.
Phase 2/3
256
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-01-27
Active, closed
An Open Label 100 Person Study Evaluating a Natural Supplement for Weight Loss and Fat Loss.
NCT07152470Overweight and Obesity
Prostasis, LLC, dba Tonum Health
Observational
100
Florida
2025-01-26
Recruiting
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360NonSegmental Vitiligo
DrugRuxolitinib
Incyte Corporation
Phase 3
180
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-01-24
Recruiting
A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)
NCT06721143Chronic Kidney Disease Stage 3
AION Healthspan, Inc.
Phase 1/2
36
Florida
2025-01-23
Recruiting
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
United Therapeutics
Observational
900
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-01-23
Recruiting
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT06697184Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 1/2
258
Florida, Indiana, Kansas, Massachusetts, Missouri, Washington
2025-01-23
Active, closed
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773Geographic Atrophy, Macular Degeneration
DrugAvacincaptad Pegol
Astellas Pharma Global Development, Inc.
Observational
489
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2025-01-22
Active, closed
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
Cogent Biosciences, Inc.
Phase 1/2
110
California, Florida, Illinois, Massachusetts, Minnesota, Ohio, Pennsylvania, Tennessee
2025-01-22
Recruiting
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624Major Depressive Disorder
DrugNBI-1065845
Neurocrine Biosciences
Phase 3
200
Arkansas, California, Florida, Massachusetts, New York, Ohio, Texas, Washington
2025-01-22
Recruiting
Serranator POINT FORCE Registry
NCT06687590Peripheral Artery Disease (PAD), Dysfunctional AV Fistula, Dysfunctional AV Graft
Cagent Vascular LLC
Observational
500
Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri, New Jersey
2025-01-22
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
240
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-01-21
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
NCT06613360SLE, SLE (Systemic Lupus)
DrugCLN-978
Cullinan Therapeutics Inc.
Phase 1
24
Arizona, Florida, Iowa, New York, Tennessee, Texas, Utah
2025-01-21
Recruiting
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06568939Non-Small Cell Lung Cancer
DrugTelisotuzumab vedotin
AbbVie
Phase 2
150
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-01-20
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
NCT06632951Urothelial Carcinoma
DrugsLivmoniplimab·Budigalimab·Gemcitabine·Paclitaxel
AbbVie
Phase 2
150
Arkansas, California, Connecticut, Delaware, Florida, New York, Ohio, Tennessee
2025-01-20
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
Neuron23 Inc.
Phase 2
150
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-01-17
Active, closed
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults
NCT06786520HIV Infections
DrugsCab Ula·Cab La
ViiV Healthcare
Phase 1
69
Alabama, Florida, Illinois
2025-01-17
Recruiting
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
NCT06182397Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Concept Medical Inc.
Not applicable
368
Arizona, California, Florida, Iowa, Michigan, New Jersey, New York, Ohio
2025-01-16
Recruiting
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
NCT06555419Muscular Atrophy, Spinal
DrugNusinersen
Biogen
Phase 1
78
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Pennsylvania, Texas
2025-01-16
Active, closed
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
NCT06634420Hereditary Angioedema
Intellia Therapeutics
Phase 3
80
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio
2025-01-15
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847Primary Sjogrens Disease
DrugEfgartigimod PH20
argenx
Phase 3
631
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-15
By invitation
An Investigational Study Examining the Cross-Validation of QbMobile in ADHD and Normative Populations
NCT07220330No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD), Healthy Volunteer
Qbtech AB
Observational
700
California, Florida
2025-01-15
By invitation
An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD
NCT07217977Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
Qbtech AB
Observational
175
Alabama, California, Florida, North Carolina, Texas
2025-01-15
Recruiting
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543Colorectal Cancer
DrugFruquintinib
Takeda
Phase 4
78
Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Indiana
2025-01-14
Active, closed
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
NCT06456463Acute Myeloid Leukemia
DrugsAzacitidine·Venetoclax
Stemline Therapeutics, Inc.
Phase 2
85
California, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey, New York
2025-01-14
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
DrugZanidatamab
Jazz Pharmaceuticals
Phase 2
200
Arizona, Colorado, Florida, Illinois, Michigan, New York, Pennsylvania, Tennessee
2025-01-14
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126Melanoma, Cutaneous Malignant
DrugsIMA203·Lifileucel·Relatlimab·Dacarbazine
Immatics US, Inc.
Phase 3
360
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2025-01-14
Active, closed
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
NCT06715124Advanced Solid Tumors
Quanta Therapeutics
Phase 1
237
Colorado, Connecticut, Florida, Michigan, North Carolina, Tennessee, Texas, Utah
2025-01-14
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Alabama, Arizona, California, Colorado, Connecticut, Florida, Hawaii, Illinois
2025-01-13
Recruiting
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
NCT06011551Degenerative Disc Disease (DDD)
ReGelTec, Inc.
Not applicable
225
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kansas, Louisiana
2025-01-13
Active, closed
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016Female Contraception
Mylan Pharmaceuticals Inc
Phase 3
1,630
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky
2025-01-13
Recruiting
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
NCT06516653End Stage Renal Disease
Laminate Medical Technologies
Not applicable
300
California, Florida, Georgia, Massachusetts, Mississippi, Nevada, South Carolina, Texas
2025-01-13
Recruiting
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122Type 2 Diabetes
DrugDulaglutide
Eli Lilly and Company
Phase 3
55
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-01-10
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
NCT06740630Chickenpox
DrugMMR vaccine
GlaxoSmithKline
Phase 3
1,840
Alabama, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-10
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462Rheumatoid Arthritis
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
120
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-01-10
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
BeOne Medicines
Phase 1
525
California, Florida, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-01-10
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226Sickle Cell Disease, Thalassemia
Novo Nordisk A/S
Phase 3
480
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-01-10
Recruiting
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
NCT06908356Focal Onset Seizure, Primary Generalized Epilepsy
Praxis Precision Medicines
Phase 2
50
Arizona, Florida, Maryland, Missouri, New Jersey, New York, Texas
2025-01-10
Active, closed
Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)
NCT06852768oGHVD
Regenerative Ocular Immunobiologics LLC
Phase 1/2
15
California, Florida, Kentucky, Massachusetts
2025-01-10
Recruiting
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT06706076NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics
Phase 1/2
675
Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Michigan
2025-01-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Arizona, Arkansas, Florida, Illinois, Maryland, Massachusetts, Minnesota, New Mexico
2025-01-09
Recruiting
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
NCT06809179Social Anxiety Disorder
VistaGen Therapeutics, Inc.
Phase 2
60
California, Florida, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, Texas
2025-01-09
Rows per page Showing 1701–1800 of 4401
Previous 16 17 18 19 20 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/florida?page=18

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 4,401 of those studies with a site in Florida.

How many clinical trials are recruiting in Florida?

2,364 of the 4,401 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 103 have not yet opened recruitment, 1,825 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.